Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Revenue of Biofrontera Inc. (BFRI)
Revenue in 2023 (TTM): $34.07 M
According to Biofrontera Inc.'s latest financial reports the company's current revenue (TTM) is $34.07 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Biofrontera Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $34.07 M | $16.63 M | $-18,453,000 | $-20,117,000 | $-20,131,000 |
| 2022 | $28.67 M | $13.49 M | $934 K | $-608,000 | $-640,000 |
| 2021 | $24.1 M | $11.36 M | $-36,757,000 | $-37,657,000 | $-37,713,000 |
| 2020 | $18.85 M | $9.78 M | $-7,492,000 | $-10,923,000 | $-10,987,000 |
| 2019 | $26.18 M | $13.77 M | $-8,148,000 | $-10,949,000 | $-10,982,000 |